2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-108341
    PF-06424439 1469284-78-3 99.89%
    PF-06424439 is an oral, potent and selective imidazopyridine diacylglycerol acyltransferase 2 (DGAT2) inhibitor with an IC50 of 14 nM. PF-06424439 is slowly reversible, time-dependent inhibitor, which inhibits DGAT2 in a noncompetitive mode with respect to the acyl-CoA substrate.
    PF-06424439
  • HY-134495
    N-Acetyl-L-cysteine ethyl ester 59587-09-6 99.87%
    N-Acetyl-L-cysteine ethyl ester is an esterified form of N-acetyl-L-cysteine (NAC). N-Acetyl-L-cysteine ethyl ester exhibits enhanced cell permeability, and produce NAC and cysteine. N-Acetyl-L-cysteine ethyl ester increases circulating hydrogen sulfide (H2S) and can be used as an H2S producer. N-Acetyl-L-cysteine ethyl ester has the potential to substitute NAC as a mucolytic agent, and as a GSH-related antioxidant.
    N-Acetyl-L-cysteine ethyl ester
  • HY-W013494
    L-Carnosine 305-84-0 ≥98.0%
    L-Carnosine is a dipeptide composed of beta-alanine and histidine. L-Carnosine is an endogenous metabolite found in human brain, muscle and gastrointestinal tissues and is present in all vertebrates. L-Carnosine is a non-enzymatic free radical scavenger and natural antioxidant with anti-inflammatory and neuroprotective properties that can inhibit biochemical changes associated with aging.
    L-Carnosine
  • HY-Y1878C
    Copper sulfate anhydrous, 99% 7758-98-7 99.65%
    Anhydrous copper sulfate, 99% (Cupric sulfate anhydrous, 99%) is an orally administerable disinfectant. Anhydrous copper sulfate, 99% can be used as a biomaterial or organic compound related to life sciences research, and it can increase the Cu content in rat organs.
    Copper sulfate anhydrous, 99%
  • HY-15262
    SRT 2104 1093403-33-8 99.00%
    SRT 2104 is a first-in-class, highly selective and brain-permeable activator of the NAD+ dependent deacetylase Sirt1, increases Sirt1 protein, but shows no effect on Sirt1 mRNA. Used in the research of diabetes mellitus and Huntington’s disease.
    SRT 2104
  • HY-15516
    Sotagliflozin 1018899-04-1 99.89%
    Sotagliflozin (LX-4211) is a potent dual SGLT2/1 inhibitor. Antidiabetic agents.
    Sotagliflozin
  • HY-B0388
    Probucol 23288-49-5 ≥98.0%
    Probucol (DH-581) is an anti-hyperlipidemic agent. Probucol activates glutathione peroxidase. Probucol promotes low density lipoprotein (LDL) catabolism, inhibits ABCA1-dependent cholesterol efflux, and decreases HDL-C levels. Probucol also has anti-inflammatory, antioxidant and neuroprotective properties. Probucol can be used for researches on bone, cardiovascular, cancer, neurological, and metabolism-related diseases.
    Probucol
  • HY-B0586
    Methylcobalamin 13422-55-4 99.02%
    Methylcobalamin (CH3-B12), a cobalamin, is a form of vitamin B12.
    Methylcobalamin
  • HY-145934
    UDP-GalNAz disodium 653600-61-4 99.78%
    UDP-GalNAz (UDP-N-azidoacetylgalactosamine) disodium is the analogue of UDP-GalNAc (HY-114365). UDP-GalNAc is the donor substrate of many N-acetylgalactosaminyltransferases, enzymes which transfer GalNAc from the nucleotide sugar to a saccharide or peptide acceptor. UDP-GalNAz (disodium) is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
    UDP-GalNAz disodium
  • HY-W010382
    Oxaloacetic acid 328-42-7 ≥98.0%
    Oxaloacetic acid (2-Oxosuccinic acid) is a metabolic intermediate involved in several ways, such as citric acid cycle, gluconeogenesis, the urea cycle, the glyoxylate cycle, amino acid synthesis, and fatty acid synthesis, whereby Oxaloacetic acid facilitates the clearance of reactive oxygen species (ROS) and improves mitochondrial function.
    Oxaloacetic acid
  • HY-N2302
    Fucoxanthin 3351-86-8 ≥98.0%
    Fucoxanthin (all-trans-Fucoxanthin) is a marine carotenoid and shows anti-obesity, anti-diabetic, anti-oxidant, anti-inflammatory and anticancer activities.
    Fucoxanthin
  • HY-114118A
    Semaglutide TFA 99.92%
    Semaglutide TFA is a long-acting, selective, competitive, orally active GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer.
    Semaglutide TFA
  • HY-114392
    Gly-β-MCA 66225-78-3 ≥98.0%
    Gly-β-MCA, a bile acid, is a potent, sable, intestine-selective and oral bioactive farnesoid X receptor (FXR) inhibitor that may be a candidate for the treatment of metabolic disorders.
    Gly-β-MCA
  • HY-W012530
    Phenylpyruvic acid 156-06-9 ≥98.0%
    Phenylpyruvic acid is a precursor of the antifungal compound phenyllactic acid. Phenylpyruvic acid can improve the antifungal activity of eight lactic acid bacterial strains through the addition into a dedined growth medium. Phenylpyruvic acid demonstrates improved inhibitory activity against fungal bread contaminants Aspergillus niger and Penicillium roqueforti. Phenylpyruvic acid affects enzyme activity of the pentose phosphate pathway involved in the oxidative phase in rat brain homogenates. Phenylpyruvic acid can reduce glucose-6-phosphate dehydrogenase activity.
    Phenylpyruvic acid
  • HY-14823
    Sobetirome 211110-63-3 ≥98.0%
    Sobetirome (GC-1) is a thyroid hormone receptor β (TRβ)-specific agonist which bind selectively to TRβ-1 with an EC50 of 0.16 μM.
    Sobetirome
  • HY-13928
    GW0742 317318-84-6 99.94%
    GW0742 is a potent PPARβ and PPARδ agonist, with an IC50 of 1 nM for human PPARδ in binding assay, and EC50s of 1 nM, 1.1 μM and 2 μM for human PPARδ, PPARα, and PPARγ, respectively.
    GW0742
  • HY-A0210
    Cerulenin 17397-89-6 ≥99.0%
    Cerulenin, a potent, natural inhibitor of fatty acid synthase (FASN), is an epoxide produced by the fungus Cephalosporium caeruleus. Cerulenin inhibits topoisomerase I catalytic activity and augments SN-38-induced apoptosis. Cerulenin has antifungal and antitumor activies.
    Cerulenin
  • HY-112540B
    Acetoacetic acid sodium 623-58-5 ≥98.0%
    Acetoacetic acid sodium is an oxidative stress inducer that affects the antioxidant enzyme system and lipoprotein metabolism. Acetoacetic acid sodium induces oxidative stress by decreasing the mRNA expression and activity of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px), increasing MDA content, and inhibiting very low density lipoprotein (VLDL) assembly by downregulating apolipoprotein ApoB100, ApoE, and low density lipoprotein receptor (LDLR), leading to triglyceride (TG) accumulation in hepatocytes. Acetoacetic acid sodium can be used to study metabolic diseases.
    Acetoacetic acid sodium
  • HY-A0132
    N-Acetyl-D-glucosamine 7512-17-6 ≥98.0%
    N-Acetyl-D-Glucosamine (N-Acetyl-2-amino-2-deoxy-D-glucose), the D isomer of N-acetylglucosamine, is an orally active monosaccharide derivative of glucose with anti-tumor and anti-inflammation properties. N-Acetyl-D-Glucosamine is also a bacterial metabolite, which is found in Escherichia coli. N-Acetyl-D-Glucosamine can induce yeast-mycelial conversion in Candida albicans. N-Acetyl-D-Glucosamine also enhances healing of cartilaginous injuries in rabbits.
    N-Acetyl-D-glucosamine
  • HY-D1168
    Oil Red O 1320-06-5
    Oil Red O is a fat-soluble diazol dye, with a maximum absorption at 518 nm. Oil Red O stains neutral lipids and cholesteryl esters but not biological membranes. Oil Red O can be used for detecting and quantifying hepatic steatosis in mouse liver biopsies. Oil Red O staining efficiently helps to visualize the radical changes that occur in tissues as metabolic disease occurs and progresses.
    Oil Red O
Cat. No. Product Name / Synonyms Application Reactivity